Researchers from Egypt, India, and the UK are studying the role of 3D printing in drug delivery systems. Their findings are detailed in the recently released ‘Pharmaceutical Particulates and Membranes for the Delivery of Drugs and Bioactive Moleclules,’ as they review new trends and developments.
In reviewing twelve different papers on the subject of pharmaceutical particulates and membranes, the researchers also collaborated with experts regarding design, materials, and applications; for instance, in a study by Kumar et al. , the researchers learned of an extended release drug delivery system for nicotine that shows potential for Parkinson’s disease interventions:
“These have been developed in the form of membranes with minimal rates of matrix degradation and retarding nicotine release. This has led to the zero-order release for 50 days following exposure to simulated cerebrospinal fluid (CSF),” stated the researchers.
Mora-Espíet et al.  have explored the targeting of microparticles and culturing breast cancer cell lines. Huang et al.  confirmed a new process for accelerating drug dissolution with ibuprofen-loaded hydroxypropyl methylcellulose nanoparticles.
“During this process, it was shown that a key parameter, i.e., the spreading angle of atomization could provide a linkage among the working process, the property of generated nanoparticles and their functional performance,” stated the researchers. “They confirmed that the nanoparticle diameter (prepared based on a modified technique) has a profound influence on the drug release performance.”
Shah et al.  contributed a study as they moved forward to refine the effectiveness of moxifloxacin, an antibiotic used to treat a variety of bacterial infections. With a new system for optimizing nanoemulsion, they were able to ‘enhance the therapeutic effects of moxifloxacin,’ resulting in safe delivery.
Another development, contributed by Wan et al. , allowed for sustained release of loxoprofen sodium (LXP), with the addition of a unique coating:
“Their results identified both the citric acid (CA) and ADEC as the dissolution and diffusion-rate controlling materials significantly decreasing the drug release rate,” stated the researchers. “The optimal formulation for a pH-independent drug release in media has been suggested as at a pH above 4.5 and at slightly slow release in acid medium.
“The pharmacokinetic studies have revealed that a more stable and prolonged plasma drug concentration profile of the optimal pellets has been achieved, with a relative bioavailability of 87.16% compared with the conventional tablets.”
Studying magnetic nanoparticles, Iglesias et al.  stated that BMNPs (biometic) were superior to MNPs (inorganic) for drug loading of molecules ‘positively charged at neutral pH.’ MNPs, however, have the potential for suitable transport abilities while under a magnetic field. Savin et al  explored gel formulations for skin melanoma treatment, along with fabricating breast cancer cells in 3D models—following one of the major trends in medicine today using models for treatment, training, and surgical planning too.
“The in vitro results for the tested CD-NHF-loaded gel formulations have revealed that the new composites can affect the number, size, and cellular organization of spheroids and impact individual tumor cell ability to proliferate and aggregate in spheroids,” stated the researchers.
Guadarrama-Acevedo et al.  created a new wound dressing made of alginate membrane and polycaprolactone nanoparticles, loaded with curcumin for healing. Integrating nanocarriers allows for drug permeation into multiple layers of skin, thus eliminating solubility issues with curcumin. Rancan et al.  performed research showing that after six hours, nanofiber mats offer the best drug concentration upon delivery.
Further, Lian et al.  developed a system for using red blood cell membrane-camouflaged ATO-loaded sodium alginate nanoparticles (RBCM-SA-ATO-NPs, RSANs) to eliminate toxicity of ATO. Their work also showed that RSANS have lower levels of cytotoxicity, upon comparison with normal cells; RSANS also displayed antitumor effects on NB4 cells and 7721 cells.
Adeleke et al.  developed an isoniazid suspension as an antitubercular agent against TB, offering extended release:
RDS has been dispersible and stable in the dried and reconstituted states over 4 months and 11 days respectively, under common storage conditions.
“The published papers are also being compiled as an edited e-book, to be published by MDPI,” stated the researchers.
What do you think of this news? Let us know your thoughts! Join the discussion of this and other 3D printing topics at 3DPrintBoard.com.[Source / Images: ‘Pharmaceutical Particulates and Membranes for the Delivery of Drugs and Bioactive Moleclules’]
Subscribe to Our Email Newsletter
Stay up-to-date on all the latest news from the 3D printing industry and recieve information and offers from thrid party vendors.
You May Also Like
3D Printing News Unpeeled, Live with Joris Peels Wednesday 17th of August
Today we’re talking about Spectroplast brings a silicone 3D printer on the market, the Pylo 3D printed bike helmet, a study on the effects 3D printing has on global trade,...
3D Printing News Unpeeled, Live with Joris Peels Tuesday 16th of August
Today we’re discussing a revolutionary new open printer for soft materials developed by Cambridge University researchers, Czinger making parts for Aston Martin, Astro America and America Makes BBF? and Craft...
3D Printing News Unpeeled, Live with Joris Peels Monday 15th of August
Today we’re looking at a company that says it is using a more sustainable 3D printing solution. As it’s using EPS foam, we’re a bit skeptical. We’re also looking at...
3D Printing Webinar and Event Roundup: August 14, 2022
This week, you can catch Markforged and Stratasys on the road, and ASTM continues its personnel certificate course. America Makes is celebrating its 10th anniversary and holding MMX, and Nexa3D...